F. HoffmannLa Roche Ltd China National Medical Products Administration grants approval of Roche\'s Tecentriq in combination with chemotherapy as firstline treatment of people with extensivestage small cell lung cancer

F. Hoffmann-La Roche Ltd: China National Medical Products Administration grants approval of Roche's Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer

This marks the first approval for a Tecentriq-based therapy in China, less than a year after the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals in this indicati...

More From BioPortfolio on "F. Hoffmann-La Roche Ltd: China National Medical Products Administration grants approval of Roche's Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer"